InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,567.19
(
1.06%
)
US TECH 100
19,829.18
(
0.96%
)
Dow Jones
39,375.87
(
0.17%
)
Brent Oil
86.78
(
-0.64%
)
Bitcoin
56,469.98
(
-0.90%
)
Post# of 26138
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Just the facts maam

Send PM Follow Ignore
Followers 20
Posts 5392
Boards Moderated 0
Alias Born 01/04/2012

Just the facts maam

Re: None

Wednesday, 02/15/2012 4:21:10 AM

Wednesday, February 15, 2012 4:21:10 AM

Post# of 26138
Consider the possibilities. Since Biosante is a science driven, research intense company as confirmed by Patent scorecard

BPAX Science Strength

It is very feasible that we could be looking at valuations similar to Regeneron ($10.19 Billion) within 5 -7 years. Possibly higher since Elestrin, Bio-t-Gel, Libigel and The Pill Plus and possibly even Cancer vaccine revenues should all create a greater annual revenue stream. I realize this is premature. But the foundation is the research and when it comes to research intensity BPAX is rated highest.

Regeneron
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up